Trial · NCT01595321
Adverse events525
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
101 to 120 of 525
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Depression | Psychiatric disorders | Cohort 2: SBRT and Modified FOLFIRINOX | 0 | 4 | 0 |
| other | Depression | Psychiatric disorders | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 3 | 12 | 3 |
| other | Diarrhea | Gastrointestinal disorders | Cohort 1: SBRT and FOLFIRINOX | 3 | 3 | 15 |
| other | Diarrhea | Gastrointestinal disorders | Cohort 2: SBRT and Modified FOLFIRINOX | 3 | 4 | 7 |
| other | Diarrhea | Gastrointestinal disorders | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 10 | 12 | 24 |
| other | Dizziness | Nervous system disorders | Cohort 1: SBRT and FOLFIRINOX | 1 | 3 | 1 |
| other | Dizziness | Nervous system disorders | Cohort 2: SBRT and Modified FOLFIRINOX | 2 | 4 | 2 |
| other | Dizziness | Nervous system disorders | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 7 | 12 | 7 |
| other | Dry Lips | Skin and subcutaneous tissue disorders | Cohort 1: SBRT and FOLFIRINOX | 0 | 3 | 0 |
| other | Dry Lips | Skin and subcutaneous tissue disorders | Cohort 2: SBRT and Modified FOLFIRINOX | 1 | 4 | 1 |
| other | Dry Lips | Skin and subcutaneous tissue disorders | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 0 | 12 | 0 |
| other | Dry mouth | Gastrointestinal disorders | Cohort 1: SBRT and FOLFIRINOX | 0 | 3 | 0 |
| other | Dry mouth | Gastrointestinal disorders | Cohort 2: SBRT and Modified FOLFIRINOX | 1 | 4 | 1 |
| other | Dry mouth | Gastrointestinal disorders | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 3 | 12 | 3 |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Cohort 1: SBRT and FOLFIRINOX | 2 | 3 | 2 |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Cohort 2: SBRT and Modified FOLFIRINOX | 0 | 4 | 0 |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 1 | 12 | 1 |
| other | Dysarthria | Nervous system disorders | Cohort 1: SBRT and FOLFIRINOX | 0 | 3 | 0 |
| other | Dysarthria | Nervous system disorders | Cohort 2: SBRT and Modified FOLFIRINOX | 1 | 4 | 1 |
| other | Dysarthria | Nervous system disorders | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 3 | 12 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01595321/events?page=6